Early clinical experience with subcutaneous GR43175 in acute migraine: an overview
- PMID: 2544287
- DOI: 10.1111/J.1468-2982.1989.TB00076.X
Early clinical experience with subcutaneous GR43175 in acute migraine: an overview
Abstract
In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
